xCures Series B: Medical Records AI Startup Raises $46 Million to Clean Up Messy Patient Data
The xCures Series B is here. xCures, a medical records AI startup, has raised $46 million in new funding to fix one of healthcare’s oldest headaches: messy patient data. Hospitals and clinics make huge piles of records every day. Most of it sits in faxes, scans, and free-form notes that computers cannot read well. xCures uses artificial intelligence (AI) to turn that mess into clean, usable information. The round was announced on June 24, 2026, and brings the company’s total funding to more than $76 million.
Here is what that means in plain words. AI is software that learns patterns from lots of examples and then does a task on its own. xCures points that software at hospital paperwork. The goal is to give doctors and researchers a clear picture of a patient’s history in seconds, not days.
Who raised the money and who paid in
The funding round was led by Innovius Capital. A “lead investor” is the firm that puts in the biggest cheque and sets the terms. Other backers joined too: iGrow, Spring Mountain Capital, and the company’s existing investors. A Series B is simply a company’s second big round of investor money. It usually comes after a startup has proven its product works and is ready to grow faster.
The new round values xCures at $127 million post-money. “Post-money valuation” means the company’s worth right after the fresh cash lands. That figure is more than double the value from its last round. xCures closed a $25 million Series A back in December 2023. So in about 18 months, investors decided the company is worth twice as much.
What xCures actually does
xCures was founded in 2018. It began as a spinout from a non-profit called Cancer Commons, started by Marty Tenenbaum. Today the chief executive is Mika Newton. The company’s core job is to take “dirty data” and make it clean.
Think of it this way. A single cancer patient might have records spread across many hospitals, labs, and clinics. Some are typed. Many are scanned images or faxes. The text inside is often messy and hard for a computer to use. xCures pulls all of it together. Its system reads documents, faxes, scans, and narrative notes. It connects to national health networks that let approved companies pull records on a patient’s behalf.
To do this, xCures mixes its own machine learning models with AI tools bought from outside vendors. “Machine learning” is the part of AI where software learns from examples instead of being told every rule by hand. The company calls its main product the “Clinical Clarity Engine.” It also builds what it describes as “decision-ready checklists from automated patient histories.” In simple terms: it turns a pile of paperwork into a short, clear summary a doctor can act on. xCures calls this whole process turning the industry’s “dirty data” into clinical intelligence.
The numbers behind the growth
The funding makes more sense when you look at how fast xCures is growing. The company says it has processed more than 300 million medical records. Those records came from over 550,000 healthcare locations. That is a huge spread of clinics and hospitals feeding data into one system.
Money is climbing fast too. ARR stands for “annual recurring revenue.” It is the steady, repeating income a company earns from its customers each year. xCures grew its ARR from $3 million in 2024 to $10 million in 2025. It projects $20 million for 2026. The company now serves 25 enterprise clients. Named customers include Exact Sciences, Caris Life Sciences, and Novocure. These are well-known names in cancer testing and treatment, which signals real trust in the product.
| Key fact | Detail |
|---|---|
| Series B amount | $46 million |
| Lead investor | Innovius Capital |
| Other investors | iGrow, Spring Mountain Capital, existing backers |
| Total raised to date | $76 million+ |
| Post-money valuation | $127 million |
| Previous round | $25 million Series A (December 2023) |
| Founded | 2018 (spinout from Cancer Commons) |
| CEO | Mika Newton |
| Records processed | 300 million+ |
| Healthcare locations | 550,000+ |
| ARR 2024 → 2025 | $3 million → $10 million |
| Projected 2026 ARR | $20 million |
| Enterprise clients | 25 |
| Announcement date | June 24, 2026 |
Why it matters (especially for India / founders)
India has the same problem, only bigger. Patient records sit in paper files, WhatsApp photos, and dozens of clinic software systems that do not talk to each other. A patient who moves from one city to another often starts from scratch. A startup that can read messy records and hand a doctor a clean summary would save time, money, and lives.
For founders, the xCures story holds three clear lessons. First, boring problems can be big businesses. Cleaning up paperwork is not glamorous, but it is worth $127 million here. Second, investors love proof. xCures tripled its revenue in a year before raising this round. Numbers like that open wallets. Third, real customers matter more than hype. Landing names like Exact Sciences gives investors confidence the product works.
This also fits a wider trend in how AI tools spread inside companies. For more on how AI is moving from labs into daily business use, see our coverage of OpenAI’s deployment chief on Codex growth and the ROI question. And for how AI is starting to write inside everyday work apps, read about how the Claude tag embeds Anthropic’s AI right inside Slack.
FAQ
What does xCures do in simple terms?
xCures uses AI to read messy medical records like faxes, scans, and notes. It then turns them into a clean, short summary that doctors and researchers can use right away.
How much did xCures raise and who led the round?
xCures raised $46 million in a Series B round. Innovius Capital led the round. iGrow, Spring Mountain Capital, and existing backers also took part. Total funding now tops $76 million.
What is ARR and why does it matter here?
ARR means annual recurring revenue, the steady yearly income from customers. xCures grew ARR from $3 million in 2024 to $10 million in 2025. Fast revenue growth like this is a big reason investors backed the company.
Who are xCures’ customers?
xCures serves 25 enterprise clients. Named customers include Exact Sciences, Caris Life Sciences, and Novocure. These are major names in cancer testing and treatment.
The takeaway
The xCures Series B shows that fixing healthcare’s data mess is now a serious, fundable business. With $46 million in fresh cash, fast-rising revenue, and big-name customers, xCures wants to become the layer that makes patient data usable. As CEO Mika Newton put it: “Healthcare has spent decades generating enormous amounts of patient data without a reliable way to make that information usable. We’re changing that.” For founders everywhere, including India, the lesson is clear. Solve a real, boring problem at scale, prove it with revenue, and the money follows.
